WEKO3
アイテム
A Phase I/II Clinical Trial of Preoperative Short-Course Carbon-Ion Radiotherapy for Patients With Squamous Cell Carcinoma of the Esophagus
https://repo.qst.go.jp/records/46370
https://repo.qst.go.jp/records/46370d50102c1-2caf-499e-b368-119c5348eb2e
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2012-07-31 | |||||
| タイトル | ||||||
| タイトル | A Phase I/II Clinical Trial of Preoperative Short-Course Carbon-Ion Radiotherapy for Patients With Squamous Cell Carcinoma of the Esophagus | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Akutsu, Yasunori
× Akutsu, Yasunori× Yasuda, Shigeo× Nagata, Matsuo× Izumi, Yousuke× Okazumi, Shin-ichi× Shimada, Hideaki× Nakatani, Yukio× Tsujii, Hirohiko× Kamada, Tadashi× Yamada, Shigeru× Matsubara, Hisahiro× 阿久津 泰典× 安田 茂雄× 永田 松夫× 出江 洋介× 岡住 慎一× 島田 英昭× 中谷 行雄× 辻井 博彦× 鎌田 正× 山田 滋× 松原 久裕 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | BACKGROUND: Carbon-ion radiotherapy (CIR) has been under development. We report the results of a phase I/II clinical trial of preoperative CIR for esophageal squamous cell carcinoma (ESCC). METHODS: Thirty-one thoracic ESCC patients were enrolled. They were first treated with CIR. The radiation dose was escalated from the initial dose of 28.8 GyE up to 36.8. Four to 8 weeks after CIR followed by clinical evaluation of the therapy, surgery was performed. Thereafter, a pathological evaluation was made. RESULTS: Acute toxicity was not seen except in one case (3.2%), and there were no late toxicities. Throughout the study period, there were no cases of withdrawal due to the effects of preoperative CIR. Twelve out of 31 (38.7%) patients achieved a clinical complete response (CR) and 13 patients (41.9%) achieved a partial response. Twelve out of 31 patients (38.7%) achieved a pathological CR. The overall 1-, 3-, and 5-year survival rates in the stage I cases were 91%, 81%, and 61%, and was 100%, 85%, and 77% for the stage II, and 71%, 43%, and 29% for the stage III cases, respectively. CONCLUSIONS: CIR showed strong local tumor control and is highly effective as a neoadjuvant therapy without severe adverse events. |
|||||
| 書誌情報 |
Journal of Surgical Oncology 巻 105, 号 8, p. 750-755, 発行日 2011-10 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0022-4790 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1002/jso.22127 | |||||
